Accord Healthcare Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Accord Healthcare Ltd.
Accord Downs Bankrupt Purdue On Abuse-Deterrent Oxycontin Patents
Intas’ Accord overcame Purdue in Hatch-Waxman litigation involving the originator’s controversial opioid, Oxycontin extended-release.
Accord Sees Benefits From Unique Portfolio
With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.
Lilly’s Omvoh Among Nine New Drugs Securing EU Marketing Thumbs Up
A number of new drugs have taken a major step towards being approved for use in the EU after receiving the nod from the European Medicines Agency’s human medicines committee, the CHMP. Meanwhile, the marketing applications for three drugs have been withdrawn.
Latuda Enters ‘Twilight’ Phase Pending Generic Competition
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
- Generic Drugs
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.